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S250 Poster Session Idemonstrated a partial response at the time of transplant. The con-
ditioning was tolerated well with no treatment related mortality
(TRM) within 100 days and no grade 4 toxicities. All pts developed
grade 1-3mucositis, while 13 reported diarrhea (7 pts grade 3) and 21
developed liver toxicity (transaminitis and/or bilirubin elevation); 2
pts with grade 3. Four pts had grade 3 lung toxicities and 1 pt grade
3 colitis. All pts engrafted: ANC.500 achieved on day 8-17 (median
10); platelets .25,000 on day 11-58 (median 18); platelets .50,000
on day 14-119 (median 23). Overall 1-yr survival is 95% (1 pt died
306 days post transplant); 3 year survival is 72%. All deaths were re-
lated to a disease recurrence: two pts with Ewing sarcoma, 2 with
rhabdomyosarcoma, and one each with neuroblastoma, Wilms and
medullodlastoma.
These data suggest that the B-M-T preparative regimen fol-
lowed by an ASCT was tolerated well without unexpected or se-
vere toxicities; pts had prompt engraftment and 0% TRM. The
survival data are encouraging compared to historical data. This
novel conditioning regimen with a favorable toxicity profile can
be used in the future as a platform for gene therapy, immune-
based cellular therapies or to intensify local control with prompt
administration of intensity modulated radiation therapy (IMRT)
such as helical-tomotherapy.
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RISK FACTORS AND CLINICAL FEATURES OF AUTOLOGOUS GRAFT-VER-
SUS-HOST DISEASE/ENGRAFTMENT SYNDROME AFTER AUTOLOGOUS
HEMATOPOIETIC CELL (HCT) TRANSPLANTATION
Cornell, R.F.1, Thompson, J.2, Drobyski, W.R.1, Fenske, T.S.1,
Horowitz, M.M.3, Palmer, J.M.1, Pasquini, M.C.3, Saad, A.A.1,
Rizzo, J.D.3, Saber, W.3, Zhang, M.-J.2, Zhong, X.3, Hari, P.1 1Medical
College ofWisconsin,Milwaukee,WI; 2Medical College ofWisconsin,Mil-
waukee, WI; 3Medical College of Wisconsin, Milwaukee, WI
Engraftment syndrome (ES) is a complication after HCT. Au-
tologous graft-versus-host disease (AGVHD) a more severe and
potentially life-threatening problem that sometimes follows ES.
The etiology for these complications remains elusive. We ana-
lyzed 315 HCT recipients for multiple myeloma (MM, n 5
210), non Hodgkin lymphoma (NHL, n 5 53), Hodgkin lym-
phoma (HL, n 5 24) and other diseases (n 5 28) to evaluate
the clinical features, frequency, risk factors and outcomes of ES/
AGVHD. ES was defined by the Spitzer and Maiolino criteria.
AGVHD was diagnosed by clinical criteria and all cases confirmed
by biopsy. ES occurred in 75 (24%) patients and 24 (7.6%) had
AGVHD (site: GI n 5 22; skin n 5 4; liver n 5 1). Diarrhea
was the most common manifestation (86%) followed by fever
(59%), skin rash (56%) and LFT abnormalities (30%). Median
time to onset of ES/AGVHD symptoms was 12 days after
HCT. To determine factors which predisposed patients to ES/
AGVHD we examined age, sex, ISS stage, conditioning regimen,
disease type, prior chemotherapy exposure, growth factor exposure
and CD34+ cell count in a multivariate model. Patients with ES/
AGVHD had prolonged hospital stays (p\0.0001). Most AGVHD
patients required higher dose and exposure to corticosteroids
(96%) compared with those with ES (61%) p\0.0001.
By univariate analysis, older age, MM and exposure to bortezomib
or lenalidomide were more likely to develop ES or AGVHD (p 5
0.0006). See Table 1.
Inmultivariatemodels,MMwasmost strongly associated with de-
velopment of ES/AGVHD (p\0.0001) compared to lymphoma or
other diseases. Higher stage MM (ISS III; p 5 0.0177) and the use
of thalidomide, lenalidomide or bortezomib prior to HCT (p 5
0.0009) were associated with development of ES/AGVHD. At me-
dian follow-up of 28 months, there was no difference in overall sur-
vival.
In conclusion, these data demonstrate that ES and AGVHD are
relatively common complications after HCT, occurring in about
one-third of patients. Affected patients had diarrhea, non-infectious
fevers, longer hospitalization and increased morbidity. Early recog-
nition of these conditions is important to initiate appropriate treat-
ment and avoid unnecessary complications. The vast majority were
successfully treated with a short course of corticosteroids. In the
era of immunomodulatory drugs and bortezomib for MM, these
data suggest that the underlying biology of MM and modern treat-
ments may predispose patients to development of these conditions
in the early engraftment period.Table 1. Characteristics of patients without ES/AGVHD vs.
patients with ES/AGVHD
Patient No ES/ ES/ P-value P-valueCharacteristics AGVHD AGVHD (Univariate) (Multivariate)Number of patients 216 99Age at transplant,
median (range), years58 (18-79) 61 (26-77) 0.0006GenderMale 138 (64) 56 (57) 0.2148DiseaseMultiple Myeloma 123 (57) 87 (88) <0.0001 <0.0001Lymphoma 66 (31) 11 (11) 0.0002Others 27 (12) 2 (2) 0.0026International StageStage III 12 (6) 21 (21) <0.0001 <0.0047Chemotherapy <0.0009Prior Lenalidomide 36 (17) 30 (30) 0.0058Prior Bortezomib 84 (39) 64 (65) <0.0001Prior Thalidomide 19 (9) 15 (15) 0.0915Other prior chemotherapy 115 (72) 64 (65) 0.0230ConditioningMel 125 (56) 82 (83) <0.0001BEAM 72 (33) 9 (9) <0.0001CyTBI 3 (1) 2 (2) 0.6512Growth FactorPegfilgrastim 22 (10) 9 (9) 0.7921Filgrastim 192 (89) 88 (89) 0.9999CellularityCD34+ cell/kg, median X106 5 5 0.4149Median days from
transplant to
discharge (range)15 (7-94) 17 (6-164) <0.0001OutcomesOverall survival
(prob 95% CI)At 12 months 86 (80-90) 89 (79-94) 0.839At 36 months 74 (67-80) 82 (70-90) 0.182Death rate
(point estimate)At 100 days 4 (2-7) 3 (2-7)125
OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PHILA-
DELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Keyzner, A., Donahue, L.L., Bayer, R.L. Hofstra University School of
Medicine - North Shore LIJ Health System, Lake Success, NY
Purpose: Patients with Ph+ALL have very poor outcomes in the ab-
sence of allogeneic stem cell transplant. Allogeneic stem cell trans-
plantation, even with reduced intensity preparative regimens, is
associated with higher rates of mortality and morbidity as compared
to conventional chemotherapy or autologous stem cell transplanta-
tion. HLA matched donors are not always available and certain pa-
tients may not be good candidates for this procedure. The best
treatment alternatives to allogeneic stem cell transplant are not
known in the current era of tyrosine kinase inhibitor (TKI) use.
Autologous stem cell transplantation has been attempted in the
pre-TKI era with very limited success. We report outcomes of eight
patients with Ph+ALL treated with autologous stem cell transplanta-
tion in combination with TKI use pre and post transplant.
Method/Results:We treated 8 patients with Ph+ ALL, between the
years of 2004 to 2010, who did not have an available HLA-compat-
ible donor with autologous stem cell transplantation. All patients un-
derwent standard induction chemotherapy for ALL in combination
with Imatinib. One patient who did not achieve complete molecular
remission following induction chemotherapy with Imatinib received
Dasatinib. Complete molecular remission was documented in all pa-
tients prior to peripheral blood stem cell (PBSC) mobilization with
VP-16/Ara-C. Seven patients received TBI/Cytoxan/Etoposide as
their preparative regimen and one patient received Busulfan/Cy-
toxan. All but one patient engrafted neutrophils at median 10 days
(range 9-56) and platelets at median 21 days (range 9-.365). One pa-
tient died prior to engraftment. Following recovery of counts
Poster Session I S251patients were re-started on a tyrosine kinase inhibitor (Imatinib -5,
Dasatinib -1). One patient had delayed recovery of blood counts
and was not restarted on a TKI. One patient relapsed 4 months
post PBSCT and died due to refractory disease. Remaining patients
remain alive at median 26 months (range 12-86) in complete molec-
ular remission. Of note the patient that never received post-trans-
plant TKI remains in complete molecular remission 86 months
following PBSCT.
Conclusion: Autologous stem cell transplantation in combination
with tyrosine kinase inhibition can provide long term durable remis-
sions in patients with Ph+ ALLwho are unable to undergo allogeneic
stem cell transplantation.
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COMPARISON OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTATION WITH AND WITHOUT METAIODOBENZYLGUANIDINE
(MIBG) IN PATIENTS WITH HIGH RISK NEUROBLASTOMA
Hamidieh, A.A.1, Beigi, D.2, Fallahi, B.2, Behfar, M.1, Jalili, M.1,
Hamdi, A.1, Hosseini, A.1, Ghavamzadeh, A.1 1Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran; 2Tehran University
of Medical Sciences, Tehran, Islamic Republic of Iran
Background: Autologous Hematopoietic Stem Cell transplantation
(auto-HSCT) has been considered for treatment of patients with
high risk neuroblastoma. In this study we compared two main
strategies of auto-HSCT for patients with high risk neuroblastoma:
auto-HSCT alone in patient with negative diagnostic MIBG and
auto-HSCT with therapeutic MIBG before HSCT in patient with
positive diagnostic MIBG.
Methods: The results of 14 patients with high risk neuroblastoma
who underwent auto-HSCT at our center from 2008 to 2011,
were analyzed. Median age at transplantation was 4.5 years (range
5 2-7, 50% male). N-Myc amplification was positive in 9 patients
(64.3%). Diagnostic MIBG was asked at first visit from all patients
who were referred to our center for HSCT. Patients were divided
into two groups according to the result of diagnostic MIBG:
MIBG-avid (n 5 6) and non MIBG-avid (n 5 8). MIBG-avid pa-
tients received 131I-MIBG (12 mci/kg) on day 21 before transplanta-
tion. The conditioning regimen used in all patients consisted of
etoposide (1200mg/m2 total dose divided for 5 days), carboplatin
(1500mg/m2 total dose divided for 5 days), and melphalan (210mg/
m2 total dose divided for 3 days). The source of stem cells was pe-
ripheral blood in patients. The median numbers of MNC and
CD34 injected were 10.71x108/kg /kg, 1.7x106/kg, respectively. All
patients received 13-cis-retinoic acid (120-160 mg/m2 2 weeks per
month) from day +60 to one year after transplantation.
Results: Engraftment occurred in all patients. The median time to
neutrophil and platelet engraftment were 13 (10-18 days) and 17
days (13-21 days), respectively that was not significantly different
between two groups. No severe side effects (like neutropenia, throm-
bocytopenia and mucusitis) were observed in any patients in MIBG-
avid group. With a median follow-up time of 13 months (2-35
months), 2 patients (33.3%) relapsed in MIBG-avid group (both
died) and 5 patients (62.5%) relapsed in non MIBG-avid group (4
of them died).
Conclusion:Despite nonsignificant difference between two groups,
MIBG-avid patients seem to have better survival and lower relapse
rate. Therefore, much greater number of cases is needed to clarify
the role of MIBG therapy in pre-transplant conditioning regimen
for autologous hematopoietic stem cell transplantation in high risk
neuroblastoma patients.127
COMPARISON OF BUSULFAN +MELPHALAN TOMELPHALAN 200 MG/M2
AS PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION IN
MULTIPLE MYELOMA
Ahmed, S., Dinh, Y., Rondon, G., Andersson, B., Jones, R., Bashir, Q.,
Shah, N., Popat, U., Champlin, R.E., Qazilbash, M.H., Kebriaei, P.
The University of Texas, M.D. Anderson Cancer Center, Houston, TX
Background:High-dose chemotherapy with melphalan 200 mg/m2
(Mel 200) followed by autologous hematopoietic stem cell transplan-tation (auto-HCT) is the standard treatment for transplant-eligible
patients (pts) withmultiplemyeloma (MM).Most patients eventually
relapse after auto-HCT and in efforts to improve the efficacy of the
preparative regimen, several groups have evaluated the combination
of busulfan (Bu) and melphalan (Mel). We studied the safety and ef-
ficacy of a combination of Bu and Mel (Bu-Mel) in patients with ad-
vanced lymphoid malignancies, including MM. (Kebriaei P, et al.,
Biol Blood Marrow Transplant 2011; 17: 412-420). In this study
we compared outcomes of patients with MM who received Bu-Mel
with a control group of patients who received Mel 200 for auto-
HCT for MM.
Methods: We identified 30 patients with MM in first remission
who received Bu-Mel followed by auto-HCT between 1/2005
and 10/2010. They were compared to a control group (4:1) of
120 patients with MM who received Mel 200 as conditioning reg-
imen for auto-HCT. The groups were matched for year of auto-
HCT, age at auto-HCT (+/- 4 yrs), cytogenetic abnormalities,
and disease status at auto-HCT. The primary objective was to
study impact of conditioning regimens on complete (CR) and
overall response rate (ORR), progression-free (PFS) and overall
survival (OS).
Results: Patient characteristics and major outcomes are summa-
rized in the attached Table. Bu-Mel and Mel 200 groups were
similar in median age, renal function and chemosensitivity at auto-
HCT, and time from diagnosis to auto-HCT (Table). Median
time to neutrophil engraftment in both groups was 10 days (p 5
0.8). There was no significant difference in 100-day transplant-
related mortality (0% vs. 0.8%, p 5 0.2) or grade 2-4 non-he-
matologic toxicity between Bu-Mel and Mel 200 (80% vs. 66%, p
5 0.18) or veno-occlusive disease (none in either group). CR rates
in Bu-Mel and Mel 200 were 30% vs. 34% (p 5 0.82, Table).
Median follow up was 27.3 months. Median PFS for Bu-Mel and
Mel 200 were 24.1 and 26.2 months, respectively (p 5 0.43,
Figure 1). Median OS for Bu-Mel and Mel 200 has not yet been
reached (p 5 0.24, Figure 2).
Conclusions: In this large single center study with long follow up,
we demonstrated that a preparative regimen of Bu-Mel is compara-
ble to Mel 200 in safety and efficacy. The two regimens will be com-
pared in a prospective, randomized trial.
Table. Patient Characteristics/Outcomes
Bu-Mel (n 5 30) Mel200 (n 5 120) pMales 17 68 1.00
Median Age 52.5 52 0.19
Abn Cytogenetics 12 48 1.00
High Risk CG 2 8 1.00
Serum Creat > 1.5 at TP 1 8 0.68
Median Interval Dx to TP 6.8 mo 6.7 mo 0.44
Median CD34 4.63 4.76 0.31
Chemosensitive (>/ 5 atTP) 13% 9% 0.50
Median days to engraftment
ANC ./ 5 50010 10 0.81CR 9, 30% 41, 34% 0.82
CR + VGPR 20, 66% 72, 60% 0.53
ORR 27, 90% 110, 83% 0.57
100-day TRM 0 1, 0.8% 0.20
Grade 2-4 AE 24, 80% 79, 66% 0.18
Median PFS 24.1 mo 26.2 mo 0.43
Median OS not reached not reached 0.24128
QUALIFICATION OF CORD BLOOD UNITS FOR AN AUTOLOGOUS
INFUSION PROGRAM FOR PEDIATRIC PATIENTS WITH ACQUIRED BRAIN
INJURIES
Allison-Thacker, J., Fitzgerald, A., Sun, J., McLaughlin, C., Waters-
Pick, B., Vinesett, R., Kurtzberg, J. Duke University Medical Center,
Durham, NC
Autologous umbilical cord blood (CB) infusion for the treatment
of brain injuries in young children has been studied by the Pediatric
Blood and Marrow Transplant (PBMT) Program at Duke Univer-
sity Medical Center since 2004. The majority of infusions have
been used to treat children with Hypoxic Ischemic Encephalopathy
